

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	19	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	20	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	21	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	22	JUL 27	CA/CAPLUS enhanced with new citing references
NEWS	23	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	24	JUL 21	USGENE adds bibliographic and sequence information
NEWS	25	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS	26	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 22:02:02 ON 02 AUG 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 22:02:10 ON 02 AUG 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JUL 2009 HIGHEST RN 1171312-62-1

DICTIONARY FILE UPDATES: 31 JUL 2009 HIGHEST RN 1171312-62-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10563474\Struc 2.str



```

chain nodes :
7 14 21 22 23
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 15 16 17 18 19 20
chain bonds :
5-7 7-8 7-23 11-14 14-15 18-22 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20
16-17 17-18 18-19 19-20
exact/norm bonds :
7-23 11-14 14-15
exact bonds :
5-7 7-8 18-22 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20
16-17 17-18 18-19 19-20

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:CLASS


```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 22:02:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 26 TO ITERATE

100.0% PROCESSED 26 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 215 TO 825
PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 22:02:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 655 TO ITERATE

100.0% PROCESSED 655 ITERATIONS 214 ANSWERS
SEARCH TIME: 00.00.01

L3 214 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 22:02:32 ON 02 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Aug 2009 VOL 151 ISS 6
 FILE LAST UPDATED: 31 Jul 2009 (20090731/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> l3

L4 9 L3

=> d ibib abs hitstr 1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1481200 CAPLUS
 DOCUMENT NUMBER: 150:29003
 TITLE: NF- κ B inhibitor-p38 MAP kinase inhibitor
 combination for the treatment of cancer and
 inflammatory diseases
 INVENTOR(S): Fu, Haiyan; Liotta, Dennis C.; Thomas, Shala L.;
 Snyder, James P.
 PATENT ASSIGNEE(S): Emory University, USA
 SOURCE: PCT Int. Appl., 122pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008150899	A1	20081211	WO 2008-US65132	20080529
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-932125P P 20070529

OTHER SOURCE(S): MARPAT 150:29003


AB The invention is directed to combinations of compds. useful in the treatment and prevention of cancer and inflammatory conditions or diseases. In particular embodiments, the combinations comprise one or more compds. that are NF- κ B inhibitors or p38 MAPK inhibitors. The invention further provides pharmaceutical compns. and methods of treatment using the combinations. In one embodiment, the NF- κ B inhibitor is a curcumin analog.

IT 464190-04-3 1092357-99-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NF- κ B inhibitor-p38 MAP kinase inhibitor combination for treatment of cancer and inflammatory diseases)

RN 464190-04-3 CAPLUS

CN Methanone, (2-chlorophenyl)[4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 1092357-99-7 CAPLUS

CN 4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-, mixt. with (2-chlorophenyl)[4-[(2,4-difluorophenyl)amino]phenyl]methanone (CA INDEX NAME)

CM 1

CRN 464190-04-3


CMF C19 H12 Cl F2 N O



CM 2

CRN 342808-40-6

CMF C19 H15 F2 N O



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1462482 CAPLUS

DOCUMENT NUMBER: 150:159389

TITLE: Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors

AUTHOR(S): Sarma, Rituparna; Sinha, Sharat; Ravikumar, Muttineni; Kumar, Madala Kishore; Mahmood, S. K.

CORPORATE SOURCE: Technocrats Industrial Estate, GVK Biosciences Pvt. Ltd., Hyderabad, A.P., 500 037, India

SOURCE: European Journal of Medicinal Chemistry (2008), 43(12), 2870-2876

CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier Masson SAS

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mitogen-activated protein (MAP) p38 kinase is a serine-threonine protein kinase and its inhibitors are useful in the treatment of inflammatory diseases. Pharmacophore models were developed using HypoGen program of Catalyst with diverse classes of p38 MAP kinase inhibitors. The best pharmacophore hypothesis (Hypo1) with hydrogen-bond acceptor (HBA), hydrophobic (HY), hydrogen-bond donor (HBD), and ring aromatic (RA) as features has correlation coefficient of 0.959, root mean square deviation (RMSD) of 1.069 and configuration cost of 14.536. The model was validated using test set containing 119 compds. and had high correlation coefficient of 0.851. The results demonstrate that results obtained in this study can be considered to be useful and reliable tools in identifying structurally diverse compds. with desired biol. activity.


IT 464190-09-8

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors)

RN 464190-09-8 CAPLUS

CN Methanone, [5-(3-amino-3-methyl-1-butyn-1-yl)-2-methoxyphenyl][4-[(2,4-

difluorophenyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:605026 CAPLUS

DOCUMENT NUMBER: 145:46069

TITLE: Preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for the treatment of inflammation, ophthalmic diseases and cancer

INVENTOR(S): Ottosen, Erik Rytter

PATENT ASSIGNEE(S): Leo Pharma A/S, Den.

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063585	A1	20060622	WO 2005-DK757	20051128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005316034	A1	20060622	AU 2005-316034	20051128
CA 2590479	A1	20060622	CA 2005-2590479	20051128
EP 1828148	A1	20070905	EP 2005-804019	20051128
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008523115	T	20080703	JP 2007-545836	20051128

MX 2007006739	A	20070802	MX 2007-6739	20070606
IN 2007DN04481	A	20070831	IN 2007-DN4481	20070612
NO 2007003574	A	20070710	NO 2007-3574	20070710
KR 2007095945	A	20071001	KR 2007-715959	20070712
CN 101115728	A	20080130	CN 2005-80048038	20070813
PRIORITY APPLN. INFO.:			US 2004-635000P	P 20041213
			DK 2004-1942	A 20041216
			WO 2005-DK757	W 20051128
OTHER SOURCE(S):			MARPAT 145:46069	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I and II [wherein R1 = Me, Cl, Br or MeO; R2 = Cl or Me; R3 = (un)substituted alkyl, alkoxy, alkenyl, etc.; R4 - R8 = H, halo, NH₂, etc., with exclusions] and pharmaceutically acceptable salts, solvates, or esters thereof were prepared as inhibitors of the production of IL-1 β and TNF- α . For instance, III was obtained by cyclization of 2-(2-azidoethoxy)tetrahydropyran with the corresponding phenylacetylene (preparation given) in the presence of copper(II) sulfate pentahydrate and sodium ascorbate. Hydrolysis of this acetal with TsOH in methanol gave a alc., which was found to be highly potent inhibitors of the production of IL-1 β and TNF- α with IC₅₀ of 1.3 nM and 0.5 nM, resp., higher than the six reference compds. The alc. was also found to be a potent p38 MAP kinase inhibitor (no data). Therefore, the invented compds. are useful, e.g., in the treatment of inflammatory, ophthalmic diseases, or cancer.

IT 890052-42-3P 890052-44-5P 890052-46-7P
890052-51-4P 890052-52-5P 890052-60-5P
890052-69-4P 890052-73-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for treatment of inflammation, ophthalmic diseases and cancer)


RN 890052-42-3 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-1,2,3-triazol-4-yl]phenyl]- (CA INDEX NAME)




RN 890052-44-5 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-1H-1,2,3-triazol-4-yl]phenyl]- (CA INDEX NAME)




RN 890052-46-7 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-51-4 CAPLUS

CN 1H-1,2,3-Triazole-1-acetic acid, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, ethyl ester (CA INDEX NAME)




RN 890052-52-5 CAPLUS

CN 1H-1,2,3-Triazole-1-acetic acid, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-60-5 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methoxy-5-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-1,2,3-triazol-4-yl]phenyl]- (CA INDEX NAME)




RN 890052-69-4 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 890052-73-0 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, methyl ester (CA INDEX NAME)



IT	890052-43-4P	890052-45-6P	890052-47-8P
	890052-48-9P	890052-49-0P	890052-50-3P
	890052-53-6P	890052-54-7P	890052-55-8P


890052-56-9P	890052-61-6P	890052-67-2P
890052-70-7P	890052-71-8P	890052-72-9P
890052-74-1P	890052-75-2P	890052-76-3P
890052-77-4P	890052-78-5P	890052-79-6P
890052-80-9P	890052-81-0P	890052-82-1P
890052-83-2P	890052-88-7P	890052-89-8P
890053-00-6P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for treatment of inflammation, ophthalmic diseases and cancer)


RN 890052-43-4 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-45-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-47-8 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2,3-dihydroxypropyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-48-9 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-49-0 CAPLUS

CN 1H-1,2,3-Triazole-1-propanesulfonamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-50-3 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-1-yl]ethyl]- (CA INDEX NAME)




RN 890052-53-6 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N-ethyl- (CA INDEX NAME)




RN 890052-54-7 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N-(2-hydroxy-1,1-dimethylethyl)- (CA INDEX NAME)




RN 890052-55-8 CAPLUS

CN Ethanone, 2-[4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-1-yl]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 890052-56-9 CAPLUS

CN Ethanone, 2-[4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-1-yl]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 890052-61-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 890052-67-2 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2-chloroethyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-70-7 CAPLUS


CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(1-hydroxy-1-methylethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-71-8 CAPLUS
 CN Ethanone, 1-[1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-4-yl]- (CA INDEX NAME)



RN 890052-72-9 CAPLUS
 CN Methanone, [5-[4-(1-amino-1-methylethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890052-74-1 CAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-75-2 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-76-3 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(3-hydroxy-1-propen-1-yl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-77-4 CAPLUS

CN Methanone, [5-[4-(2-aminoethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890052-78-5 CAPLUS

CN Urea, N-[[1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-4-yl]methyl]- (CA INDEX NAME)




RN 890052-79-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[4-[2-(4-morpholinyl)ethyl]-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)




RN 890052-80-9 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[4-[2-(4-methyl-1-piperazinyl)ethyl]-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)




RN 890052-81-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-[2-(diethylamino)ethyl]-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-82-1 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-[2-(2-hydroxyethyl)amino]ethyl]-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-83-2 CAPLUS


CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[4-[2-(propylamino)ethyl]-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)




RN 890052-88-7 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-[2-(ethylamino)ethyl]-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 890052-89-8 CAPLUS
 CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-methylphenyl][5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 890053-00-6 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-chloro-5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)



IT 835625-52-0P 890053-10-8P 890053-14-2P


890053-15-3P 890053-19-7P 890053-20-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for treatment of inflammation, ophthalmic diseases and cancer)


RN 835625-52-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] (5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 890053-10-8 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] (2-methyl-5-nitrophenyl)- (CA INDEX NAME)




RN 890053-14-2 CAPLUS

CN Methanone, (5-bromo-2-methoxyphenyl) [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-15-3 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] (5-ethynyl-2-methoxyphenyl)- (CA INDEX NAME)




RN 890053-19-7 CAPLUS

CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



RN 890053-20-0 CAPLUS

CN Methanone, [5-[4-(2-azidoethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:579261 CAPLUS

DOCUMENT NUMBER: 145:46068

TITLE: Preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for the treatment of inflammation, ophthalmic diseases and cancer

INVENTOR(S): Erik, Rytter Ottosen

PATENT ASSIGNEE(S): Leo Pharma A/S, Den.
 SOURCE: U.S. Pat. Appl. Publ., 48 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060128766	A1	20060615	US 2005-292064	20051202
ZA 2007004809	A	20080827	ZA 2007-4809	20051128
PRIORITY APPLN. INFO.:			US 2004-635000P	P 20041213
OTHER SOURCE(S):	CASREACT 145:46068; MARPAT 145:46068			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I and II [wherein R1 = Me, Cl, Br or MeO; R2 = Cl or Me; R3 = (un)substituted alkyl, alkoxy, alkenyl, etc.; R4 - R8 = H, halo, NH2, etc., with exclusions] and pharmaceutically acceptable salts, solvates, or esters thereof were prepared as inhibitors of the production of IL-1 β and TNF- α . For instance, III was obtained by cyclization of 2-(2-azidoethoxy)tetrahydropyran with the corresponding phenylacetylene (preparation given) in the presence of copper(II) sulfate pentahydrate and sodium ascorbate. Hydrolysis of this acetal with TsOH in methanol gave a alc., which was found to be highly potent inhibitors of the production of IL-1 β and TNF- α with IC50 of 1.3 nM and 0.5 nM, resp., higher than the six reference compds. The alc. was also found to be a potent p38 MAP kinase inhibitor (no data). Therefore, the invented compds. are useful, e.g., in the treatment of inflammatory, ophthalmic diseases, or cancer.

IT 1026274-28-1 1056187-96-2 1056188-08-9
 1056188-11-4 1056188-12-5
 RL: PRPH (Prophetic)
 (Preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for the treatment of inflammation, ophthalmic diseases and cancer)


RN 1026274-28-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056187-96-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056188-08-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1056188-11-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1056188-12-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 890052-42-3P 890052-44-5P 890052-46-7P
 890052-51-4P 890052-52-5P 890052-60-5P
 890052-69-4P 890052-73-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for treatment of inflammation, ophthalmic diseases and cancer)


RN 890052-42-3 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-1,2,3-triazol-4-yl]phenyl]- (CA INDEX NAME)




RN 890052-44-5 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-1H-1,2,3-triazol-4-yl]phenyl]- (CA INDEX NAME)




RN 890052-46-7 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1H-1,2,3-triazol-4-yl]-2-methylphenyl]-
(CA INDEX NAME)



RN 890052-51-4 CAPLUS


CN 1H-1,2,3-Triazole-1-acetic acid, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, ethyl ester (CA INDEX NAME)



RN 890052-52-5 CAPLUS


CN 1H-1,2,3-Triazole-1-acetic acid, 4-[3-[2-chloro-4-[(2,4-

difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-60-5 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methoxy-5-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-1,2,3-triazol-4-yl]phenyl]- (CA INDEX NAME)



RN 890052-69-4 CAPLUS


CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 890052-73-0 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid,

1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, methyl ester (CA INDEX NAME)




IT	890052-43-4P	890052-45-6P	890052-47-8P
	890052-48-9P	890052-49-0P	890052-50-3P
	890052-53-6P	890052-54-7P	890052-55-8P
	890052-56-9P	890052-61-6P	890052-67-2P
	890052-70-7P	890052-71-8P	890052-72-9P
	890052-74-1P	890052-75-2P	890052-76-3P
	890052-77-4P	890052-78-5P	890052-79-6P
	890052-80-9P	890052-81-0P	890052-82-1P
	890052-83-2P	890052-88-7P	890052-89-8P
	890053-00-6P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 β and TNF- α for treatment of inflammation, ophthalmic diseases and cancer)


RN 890052-43-4 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-45-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-47-8 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2,3-dihydroxypropyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-48-9 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-49-0 CAPLUS

CN 1H-1,2,3-Triazole-1-propanesulfonamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 890052-50-3 CAPLUS

CN Methanesulfonamide, N-[2-[4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-1-yl]ethyl]-
(CA INDEX NAME)




RN 890052-53-6 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N-ethyl- (CA INDEX NAME)




RN 890052-54-7 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, 4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N-(2-hydroxy-1,1-dimethylethyl)- (CA INDEX NAME)




RN 890052-55-8 CAPLUS

CN Ethanone, 2-[4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-1-yl]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 890052-56-9 CAPLUS

CN Ethanone, 2-[4-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-1-yl]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 890052-61-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 890052-67-2 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[1-(2-chloroethyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-70-7 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(1-hydroxy-1-methylethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-71-8 CAPLUS

CN Ethanone, 1-[1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-4-yl]- (CA INDEX NAME)




RN 890052-72-9 CAPLUS


CN Methanone, [5-[4-(1-amino-1-methylethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890052-74-1 CAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid,
 1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA
 INDEX NAME)



RN 890052-75-2 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(
 hydroxymethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-76-3 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-(3-hydroxy-
 1-propen-1-yl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-77-4 CAPLUS

CN Methanone, [5-[4-(2-aminoethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890052-78-5 CAPLUS

CN Urea, N-[[1-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-1H-1,2,3-triazol-4-yl]methyl]- (CA INDEX NAME)




RN 890052-79-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[4-[2-(4-morpholinyl)ethyl]-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)




RN 890052-80-9 CAPLUS


CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[4-[2-(4-methyl-1-piperazinyl)ethyl]-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)




RN 890052-81-0 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-[2-(diethylamino)ethyl]-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-82-1 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-[2-[(2-hydroxyethyl)amino]ethyl]-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 890052-83-2 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[4-[2-(propylamino)ethyl]-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)




RN 890052-88-7 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[4-[2-(ethylamino)ethyl]-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 890052-89-8 CAPLUS
 CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-methylphenyl][5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 890053-00-6 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-chloro-5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]phenyl]- (CA INDEX NAME)



IT 835625-52-0P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-


ethynyl-2-methylphenyl)methanone 890053-10-8P
 890053-14-2P 890053-15-3P 890053-19-7P
 890053-20-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of triazole-substituted aminobenzophenones as inhibitors of the
 production of IL-1 β and TNF- α for treatment of inflammation,
 ophthalmic diseases and cancer)


RN 835625-52-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](5-ethynyl-2-
 methylphenyl)- (CA INDEX NAME)




RN 890053-10-8 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](2-methyl-5-
 nitrophenyl)- (CA INDEX NAME)




RN 890053-14-2 CAPLUS

CN Methanone, (5-bromo-2-methoxyphenyl)[2-chloro-4-[(2,4-
 difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-15-3 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] (5-ethynyl-2-methoxyphenyl)- (CA INDEX NAME)




RN 890053-19-7 CAPLUS

CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



RN 890053-20-0 CAPLUS

CN Methanone, [5-[4-(2-azidoethyl)-1H-1,2,3-triazol-1-yl]-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:99452 CAPLUS



DOCUMENT NUMBER: 142:176548

TITLE: Preparation of novel aminobenzophenones as inhibitors of interleukin IL-1 β and tumor necrosis factor TNF- α production and their use in the treatment of inflammatory diseases and conditions

INVENTOR(S): Ottosen, Erik Rytter; Horneman, Anne Marie; Liang, Xifu; Schou, Soren Christian; Havez, Sophie Elisabeth; Sabroe, Thomas Peter

PATENT ASSIGNEE(S): Leo Pharma A/S, Den.
 SOURCE: PCT Int. Appl., 247 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009940	A1	20050203	WO 2004-DK490	20040709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259264	A1	20050203	AU 2004-259264	20040709
CA 2530302	A1	20050203	CA 2004-2530302	20040709
EP 1658263	A1	20060524	EP 2004-738987	20040709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1826310	A	20060830	CN 2004-80021378	20040709
BR 2004012893	A	20061003	BR 2004-12893	20040709
JP 2006528597	T	20061221	JP 2006-520673	20040709
ZA 2005010137	A	20070425	ZA 2005-10137	20040709
NZ 544178	A	20081128	NZ 2004-544178	20040709
US 20060166990	A1	20060727	US 2006-563474	20060105
NO 2006000230	A	20060116	NO 2006-230	20060116
MX 2006000708	A	20060419	MX 2006-708	20060118
KR 2006041270	A	20060511	KR 2006-701537	20060123
IN 2006DN00410	A	20070831	IN 2006-DN410	20060123
PRIORITY APPLN. INFO.:			US 2003-489488P	P 20030724
			WO 2004-DK490	W 20040709
OTHER SOURCE(S):			CASREACT 142:176548; MARPAT 142:176548	
GI				




- AB Title compds. I [wherein R1 = halo, OH, SH, CF₃, alk(en/yn)yl, alkoxy, CN, CONH₂, NO₂, etc.; R2 = H, halo, PH, NO₂, CONH₂, OH, SH, alk(en/yn)yl, etc.; R3 = one or more, independently H, halo, OH, SH, CN, CO₂H, NO₂, alkoxy, carbonyl, etc.; R4 = H, halo, NO₂, etc.; R5, R6 = independently H, CO₂H, CONHOH, CONHNH₂, (un)substituted alk(en/yn)yl, alkylamino, etc.; with provisos; and their pharmaceutically acceptable salts, solvates and esters] were prepared as inhibitors of interleukin IL-1 β and tumor necrosis factor TNF- α production for treating inflammation and related diseases. For example, II was prepared, in 6 steps, from 3-iodo-4-methylbenzoic acid Me ester, 2-chloro-4-nitrobenzoyl chloride, and 1-iodo-2-nitrobenzene. II displayed potent inhibitory activity against p38 α MAP kinase with IC₅₀ of 2 nM and inhibited production of IL-1 β and TNF- α in vitro with IC₅₀ values of 4.0 nM and 0.6 nM. Thus, I are useful in the treatment of inflammatory, ophthalmic diseases or cancer.
- IT 835622-90-7P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic acid 835622-92-9P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-19-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzoic acid 835624-35-6P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-methylsulfanypropionamide 835624-46-9P, 2-Methylacrylic acid 2-[3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]ethyl ester 835624-95-8P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl][5-(3-hydroxypropoxy)-2-methylphenyl]methanone 835624-99-2P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl][5-[(2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy]-2-methylphenyl]methanone 835625-00-8P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]methanone 835625-03-1P,

[2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-[(2,2-dimethyl-
[1,3]dioxolan-4-yl)methoxy]-2-fluorophenyl]methanone
835625-20-2P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl](5-
hydroxymethyl-2-methylphenyl)methanone 835625-21-3P,
[2-Chloro-4-(2,4-difluorophenylamino)phenyl](5-chloromethyl-2-
methylphenyl)methanone 835625-22-4P,
(5-Azidomethyl-2-methylphenyl)[2-chloro-4-(2,4-
difluorophenylamino)phenyl]methanone 835625-24-6P,
[2-Chloro-4-(2,4-difluorophenylamino)phenyl](5-hydroxymethyl-2-
methoxyphenyl)methanone 835625-38-2P,
4-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-
methylbenzoylamino]thiophene-3-carboxylic acid methyl ester
835625-41-7P, 2-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-
methylbenzoylamino]benzoic acid methyl ester 835625-54-2P,
3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic hydrazide
835625-55-3P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-
methylbenzoyl]-4-ethyl-3-thiosemicarbazide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(p38 α MAP kinase inhibitor; preparation of aminobenzophenones as
inhibitors of IL-1 β and TNF- α production for treating
inflammatory diseases or conditions)


RN 835622-90-7 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-
(CA INDEX NAME)




RN 835622-92-9 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-
hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-19-3 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methoxy-
(CA INDEX NAME)




RN 835624-35-6 CAPLUS

CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-(methylthio)- (CA INDEX NAME)




RN 835624-46-9 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]amino]ethyl ester (CA INDEX NAME)




RN 835624-95-8 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-99-2 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-methylphenyl]- (CA INDEX NAME)




RN 835625-00-8 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-03-1 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-20-2 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(hydroxymethyl)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-21-3 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(chloromethyl)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-22-4 CAPLUS

CN Methanone, [5-(azidomethyl)-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 835625-24-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(hydroxymethyl)-2-methoxyphenyl]- (CA INDEX NAME)




RN 835625-38-2 CAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-, methyl ester (CA INDEX NAME)




RN 835625-41-7 CAPLUS


CN Benzoic acid, 2-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-, methyl ester (CA INDEX NAME)



RN 835625-54-2 CAPLUS
 CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-, hydrazide (CA INDEX NAME)



RN 835625-55-3 CAPLUS
 CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-, 2-[(ethylamino)thioxomethyl]hydrazide (CA INDEX NAME)



IT 835622-91-8P, 2-Methylacrylic acid
 2-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]ethyl ester 835623-20-6P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methoxybenzamide 835623-21-7P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,2-difluoroethyl)-4-methoxybenzamide 835623-22-8P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methoxybenzamide 835623-23-9P,

3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxybenzamide 835623-24-0P,
 N-(Carbamoylmethyl)-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzamide 835623-25-1P,
 N-(Carbamoylmethyl)-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-26-2P,
 N-Benzyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-27-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methylbenzamide 835623-28-4P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)benzamide 835623-29-5P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-ethyl-4-methylbenzamide 835623-30-8P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-cyclohexylmethyl-4-methylbenzamide 835623-31-9P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxypropyl)-4-methylbenzamide 835623-32-0P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methylbenzamide 835623-33-1P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(1-hydroxymethylpropyl)-4-methylbenzamide 835623-34-2P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(2,2,3,3,3-pentafluoropropyl)benzamide 835623-35-3P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(3-hydroxypropyl)-4-methylbenzamide 835623-36-4P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methylbenzamide 835623-37-5P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxy-1-hydroxymethyl-1-methylethyl)-4-methylbenzamide 835623-38-6P,
 [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]acetic acid ethyl ester 835623-39-7P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(4-hydroxybutyl)-4-methylbenzamide 835623-40-0P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(3-hydroxy-1,1-dimethylbutyl)-4-methylbenzamide 835623-41-1P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(3-phenylpropyl)benzamide 835623-42-2P,
 (R)-3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(1-hydroxymethyl-3-methylbutyl)-4-methylbenzamide 835623-43-3P,
 3-[4-(2,4-Difluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methylbenzamide 835623-44-4P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-isopropyl-4-methylbenzamide 835623-45-5P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-cyclohexyl-4-methylbenzamide 835623-46-6P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,2-difluoroethyl)-4-methylbenzamide 835623-47-7P,
 5-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]-4-oxopentanoic acid methyl ester 835623-48-8P,
 N-[(2-Carbamoylethylcarbamoyl)methyl]-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-49-9P,
 [[2-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]acetyl]amino]acetic acid ethyl ester 835623-50-2P, N-Allyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-51-3P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(2-sulfamoylethyl)benzamide 835623-52-4P,
 N-(2-Acetylaminioethyl)-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-87-5P,

4-Chloro-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)benzamide 835624-25-4P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-methoxypropionamide 835624-26-5P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]propionamide 835624-27-6P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-2-(2-methoxyethoxy)acetamide 835624-28-7P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(morpholin-4-yl)propionamide 835624-29-8P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-hydroxypropionamide 835624-30-1P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(furan-2-yl)propionamide 835624-31-2P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-2-hydroxybenzamide 835624-32-3P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide 835624-33-4P
 835624-34-5P, Acrylic acid
 2-[[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamoyl]ethyl ester 835624-37-8P,
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-methylsulfonylpropionamide 835624-38-9P, Ethanesulfonic acid
 N-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]amide 835624-39-0P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-4-methoxybenzenesulfonamide 835624-40-3P,
 N-[5-[[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]sulfamoyl]-4-methylthiazol-2-yl]acetamide 835624-41-4P, 5-Acetyl-2-chloro-N-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]benzenesulfonamide 835624-42-5P, Naphthalene-2-sulfonic acid
 N-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]amide 835624-44-7P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-1-phenylmethanesulfonamide 835624-48-1P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(2-hydroxyethyl)urea 835624-49-2P,
 [3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]acetic acid ethyl ester 835624-51-6P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(3-methoxyphenyl)urea 835624-53-8P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(3-trifluoromethylphenyl)urea 835624-55-0P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-propylurea 835624-56-1P,
 3-[3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]propionic acid ethyl ester 835624-57-2P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-cyclohexylurea 835624-58-3P,
 1-Allyl-3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]urea 835624-59-4P,
 1-Benzyl-3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]urea 835624-60-7P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-ethylurea 835624-61-8P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-phenylurea 835624-62-9P,
 1-Butyl-3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-


methylphenyl]urea 835624-63-0P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-phenethylurea 835624-64-1P,
 2-[3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]benzoic acid methyl ester 835624-65-2P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(3-cyanophenyl)urea 835624-66-3P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-isopropylurea 835624-67-4P,
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(4-methoxyphenyl)urea 835624-68-5P,
 [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamic acid benzyl ester 835624-69-6P,
 [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamic acid allyl ester 835624-70-9P,
 [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamic acid ethyl ester 835624-71-0P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(3-hydroxybutylamino)-2-methylphenyl]methanone 835624-72-1P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl](3'-hydroxymethyl-4-methylbiphenyl-3-yl)methanone 835624-73-2P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl](3'-hydroxy-4-methylbiphenyl-3-yl)methanone 835624-74-3P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl](4'-methoxy-4-methylbiphenyl-3-yl)methanone 835624-75-4P,
 N-[3'-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4'-methylbiphenyl-3-yl]acetamide 835624-76-5P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl](3',4',5'-trifluoro-4-methylbiphenyl-3-yl)methanone 835624-77-6P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl](3',4'-dimethoxy-4-methylbiphenyl-3-yl)methanone 835624-78-7P,
 3'-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4'-methylbiphenyl-3-carbonitrile 835624-79-8P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzenesulfonamide 835624-80-1P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-[2-(morpholin-4-yl)ethyl]benzenesulfonamide 835624-81-2P,
 N-Allyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzenesulfonamide 835624-82-3P,
 N-[2-[[[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]sulfonyl]amino]ethyl]acetamide 835624-83-4P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-propylbenzenesulfonamide 835624-84-5P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methylbenzenesulfonamide 835624-85-6P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-methoxyethyl)-4-methylbenzenesulfonamide 835624-94-7P,
 [4-(2,4-Difluorophenylamino)-2-nitrophenyl][5-[(4-methoxybenzyl)oxy]-2-methylphenyl]methanone 835624-96-9P,
 [2-Amino-4-(2,4-difluorophenylamino)phenyl][5-(3-hydroxypropoxy)-2-methylphenyl]methanone 835624-97-0P,
 [4-(2,4-Difluorophenylamino)-2-nitrophenyl][2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl]methanone 835624-98-1P,
 [2-Amino-4-(2,4-difluorophenylamino)phenyl][2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl]methanone 835625-01-9P,
 [2-Amino-4-(2,4-difluorophenylamino)phenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]methanone 835625-02-0P,

[2-Chloro-4-(2,4-difluorophenylamino)phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]methanone 835625-04-2P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(2,3-dihydroxypropoxy)-2-fluorophenyl]methanone 835625-23-5P,
 (5-Aminomethyl-2-methylphenyl)[2-chloro-4-(2,4-difluorophenylamino)phenyl]methanone 835625-25-7P, Acetic acid
 3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzyl ester 835625-26-8P, N-tert-Butoxy-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzamide 835625-27-9P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-methoxy-4-methylbenzamide 835625-28-0P,
 N-Butoxy-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835625-29-1P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-cyclohexylmethoxy-4-methylbenzamide 835625-30-4P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-[(2-methylthiazol-4-yl)methoxy]benzamide 835625-32-6P,
 N-Benzyloxy-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835625-33-7P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-[(4-methoxybenzyl)oxy]-4-methylbenzamide 835625-34-8P,
 N',N'-Dimethyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic hydrazide 835625-35-9P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(morpholin-4-yl)benzamide 835625-36-0P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-hydroxy-4-methylbenzamide 835625-37-1P,
 4-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-3-methylbenzamide 835625-39-3P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-[(furan-2-yl)methyl]-4-methylbenzamide 835625-40-6P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(3-methoxyphenyl)-4-methylbenzamide 835625-42-8P,
 3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]thiophene-2-carboxylic acid methyl ester 835625-43-9P, 4-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]thiophene-3-carboxylic acid 835625-44-0P,
 2-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]benzoic acid 835625-45-1P,
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-[2-(2-hydroxyethylcarbamoyl)phenyl]-4-methylbenzamide 835625-46-2P,
 3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]thiophene-2-carboxylic acid (2-hydroxyethyl)amide 835625-52-0P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-ethynyl-2-methylphenyl]methanone 835625-56-4P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(5-ethylamino-1,3,4)thiadiazol-2-yl)-2-methylphenyl]methanone 835625-57-5P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][2-methyl-5-(1H-tetrazol-5-yl)phenyl]methanone 835625-58-6P 835625-59-7P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(4,5-dihydrooxazol-2-yl)-2-methylphenyl]methanone 835625-61-1P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][4-methyl-3'-(trifluoromethoxy)biphenyl-3-yl]methanone 835625-62-2P,
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(3-hydroxyprop-1-enyl)-2-methylphenyl]methanone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 α MAP kinase inhibitor; preparation of aminobenzophenones as inhibitors of IL-1 β and TNF- α production for treating inflammatory diseases or conditions)


RN 835622-91-8 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]ethyl ester (CA INDEX NAME)




RN 835623-20-6 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-21-7 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,2-difluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-22-8 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-23-9 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxy- (CA INDEX NAME)



RN 835623-24-0 CAPLUS


CN Benzamide, N-(2-amino-2-oxoethyl)-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methoxy- (CA INDEX NAME)



RN 835623-25-1 CAPLUS


CN Benzamide, N-(2-amino-2-oxoethyl)-3-[2-chloro-4-[(2,4-

difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-26-2 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 835623-27-3 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methyl- (CA INDEX NAME)




RN 835623-28-4 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 835623-29-5 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-ethyl-4-methyl- (CA INDEX NAME)




RN 835623-30-8 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(cyclohexylmethyl)-4-methyl- (CA INDEX NAME)




RN 835623-31-9 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-32-0 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-33-1 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[1-(hydroxymethyl)propyl]-4-methyl- (CA INDEX NAME)




RN 835623-34-2 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (CA INDEX NAME)




RN 835623-35-3 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(3-hydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-36-4 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methyl- (CA INDEX NAME)




RN 835623-37-5 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-4-methyl- (CA INDEX NAME)




RN 835623-38-6 CAPLUS
 CN Glycine, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]-, ethyl ester (CA INDEX NAME)




RN 835623-39-7 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(4-hydroxybutyl)-4-methyl- (CA INDEX NAME)



RN 835623-40-0 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(3-hydroxy-1,1-dimethylbutyl)-4-methyl- (CA INDEX NAME)




RN 835623-41-1 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 835623-42-2 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 835623-43-3 CAPLUS
 CN Benzamide, 3-[4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methyl- (CA INDEX NAME)




RN 835623-44-4 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 835623-45-5 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 835623-46-6 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,2-difluoroethyl)-4-methyl- (CA INDEX NAME)




RN 835623-47-7 CAPLUS
 CN Pentanoic acid, 5-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)




RN 835623-48-8 CAPLUS
 CN β -Alaninamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]glycyl- (9CI) (CA INDEX NAME)




RN 835623-49-9 CAPLUS
 CN Glycine, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]glycyl-, ethyl ester (CA INDEX NAME)




RN 835623-50-2 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-2-propen-1-yl- (CA INDEX NAME)



RN 835623-51-3 CAPLUS
 CN Benzamide, N-[2-(aminosulfonyl)ethyl]-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-52-4 CAPLUS
 CN Benzamide, N-[2-(acetylamino)ethyl]-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-87-5 CAPLUS

CN Benzamide, 4-chloro-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 835624-25-4 CAPLUS

CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-methoxy- (CA INDEX NAME)




RN 835624-26-5 CAPLUS


CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-27-6 CAPLUS
 CN Acetamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)



RN 835624-28-7 CAPLUS
 CN 4-Morpholinepropanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-29-8 CAPLUS
 CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-hydroxy- (CA INDEX NAME)




RN 835624-30-1 CAPLUS

CN 2-Furanpropanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-31-2 CAPLUS

CN Benzamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-2-hydroxy- (CA INDEX NAME)




RN 835624-32-3 CAPLUS


CN 4-Imidazolidineacetamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-2,5-dioxo- (CA INDEX NAME)




RN 835624-33-4 CAPLUS
 CN 4-Pyrimidinecarboxamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]hexahydro-2,6-dioxo- (CA INDEX NAME)



RN 835624-34-5 CAPLUS
 CN 2-Propenoic acid, 3-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]-3-oxopropyl ester (CA INDEX NAME)




RN 835624-37-8 CAPLUS
 CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 835624-38-9 CAPLUS

CN Ethanesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-39-0 CAPLUS

CN Benzenesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-4-methoxy- (CA INDEX NAME)




RN 835624-40-3 CAPLUS

CN Acetamide, N-[5-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 835624-41-4 CAPLUS

CN Benzenesulfonamide, 5-acetyl-2-chloro-N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-42-5 CAPLUS

CN 2-Naphthalenesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-44-7 CAPLUS

CN Benzenemethanesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-48-1 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)




RN 835624-49-2 CAPLUS

CN Glycine, N-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 835624-51-6 CAPLUS


CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)




RN 835624-53-8 CAPLUS
 CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)



RN 835624-55-0 CAPLUS
 CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-propyl- (CA INDEX NAME)




RN 835624-56-1 CAPLUS
 CN β -Alanine, N-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 835624-57-2 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-cyclohexyl- (CA INDEX NAME)




RN 835624-58-3 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-2-propen-1-yl- (CA INDEX NAME)




RN 835624-59-4 CAPLUS


CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 835624-60-7 CAPLUS
 CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-
 N'-ethyl- (CA INDEX NAME)



RN 835624-61-8 CAPLUS
 CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-
 N'-phenyl- (CA INDEX NAME)




RN 835624-62-9 CAPLUS
 CN Urea, N-butyl-N'-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-
 methylphenyl]- (CA INDEX NAME)




RN 835624-63-0 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(2-phenylethyl)- (CA INDEX NAME)




RN 835624-64-1 CAPLUS

CN Benzoic acid, 2-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 835624-65-2 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)




RN 835624-66-3 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 835624-67-4 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 835624-68-5 CAPLUS

CN Carbamic acid, [3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 835624-69-6 CAPLUS

CN Carbamic acid, [3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 835624-70-9 CAPLUS

CN Carbamic acid, [3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 835624-71-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[(3-hydroxybutyl)amino]-2-methylphenyl]- (CA INDEX NAME)




RN 835624-72-1 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][3'-(hydroxymethyl)-4-methyl[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 835624-73-2 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](3'-hydroxy-4-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 835624-74-3 CAPLUS


CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](4'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 835624-75-4 CAPLUS
 CN Acetamide, N-[3'-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4'-methyl[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 835624-76-5 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](3',4',5'-trifluoro-4-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 835624-77-6 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](3',4'-dimethoxy-4-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)




RN 835624-78-7 CAPLUS
 CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4'-methyl- (CA INDEX NAME)




RN 835624-79-8 CAPLUS
 CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835624-80-1 CAPLUS
 CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 835624-81-2 CAPLUS
 CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 835624-82-3 CAPLUS
 CN Acetamide, N-[2-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]sulfonyl]amino]ethyl]- (CA INDEX NAME)




RN 835624-83-4 CAPLUS
 CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-propyl- (CA INDEX NAME)




RN 835624-84-5 CAPLUS
 CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methyl- (CA INDEX NAME)



RN 835624-85-6 CAPLUS
 CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-methoxyethyl)-4-methyl- (CA INDEX NAME)




RN 835624-94-7 CAPLUS
 CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-[(4-methoxyphenyl)methoxy]-2-methylphenyl]- (CA INDEX NAME)




RN 835624-96-9 CAPLUS

CN Methanone, [2-amino-4-[(2,4-difluorophenyl)amino]phenyl][5-(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-97-0 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][2-methyl-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835624-98-1 CAPLUS

CN Methanone, [2-amino-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835625-01-9 CAPLUS

CN Methanone, [2-amino-4-[(2,4-difluorophenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-02-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-04-2 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-23-5 CAPLUS

CN Methanone, [5-(aminomethyl)-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 835625-25-7 CAPLUS

CN Methanone, [5-[(acetyloxy)methyl]-2-methoxyphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 835625-26-8 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(1,1-dimethylethoxy)-4-methoxy- (CA INDEX NAME)




RN 835625-27-9 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-methoxy-4-methyl- (CA INDEX NAME)



RN 835625-28-0 CAPLUS
 CN Benzamide, N-butoxy-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835625-29-1 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(cyclohexylmethoxy)-4-methyl- (CA INDEX NAME)




RN 835625-30-4 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-[(2-methyl-4-thiazolyl)methoxy]- (CA INDEX NAME)




RN 835625-32-6 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(phenylmethoxy)- (CA INDEX NAME)




RN 835625-33-7 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[(4-methoxyphenyl)methoxy]-4-methyl- (CA INDEX NAME)




RN 835625-34-8 CAPLUS
 CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-,
 2,2-dimethylhydrazide (CA INDEX NAME)




RN 835625-35-9 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-4-
 morpholinyl- (CA INDEX NAME)




RN 835625-36-0 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-hydroxy-4-
 methyl- (CA INDEX NAME)




RN 835625-37-1 CAPLUS
 CN Benzamide, 4-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-3-methyl- (CA INDEX NAME)




RN 835625-39-3 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-furanylmethyl)-4-methyl- (CA INDEX NAME)




RN 835625-40-6 CAPLUS
 CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 835625-42-8 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-, methyl ester (CA INDEX NAME)




RN 835625-43-9 CAPLUS
 CN 3-Thiophenecarboxylic acid, 4-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]- (CA INDEX NAME)




RN 835625-44-0 CAPLUS

CN Benzoic acid, 2-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]- (CA INDEX NAME)




RN 835625-45-1 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[2-[(2-hydroxyethyl)amino]carbonyl]phenyl]-4-methyl- (CA INDEX NAME)




RN 835625-46-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 835625-52-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] (5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 835625-56-4 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] [5-[5-(ethylamino)-1,3,4-thiadiazol-2-yl]-2-methylphenyl]- (CA INDEX NAME)




RN 835625-57-5 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl] [2-methyl-5-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 835625-58-6 CAPLUS

CN Benzenepropanoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-β-oxo-, ethyl ester (CA INDEX NAME)




RN 835625-59-7 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(4,5-dihydro-2-oxazolyl)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-61-1 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][4-methyl-3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 835625-62-2 CAPLUS
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(3-hydroxy-1-propen-1-yl)-2-methylphenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:520429 CAPLUS
 DOCUMENT NUMBER: 141:190567
 TITLE: Rapid and efficient microwave-assisted synthesis of aryl aminobenzophenones using Pd-catalyzed amination
 AUTHOR(S): Jensen, Thomas A.; Liang, Xifu; Tanner, David; Skjaerbaek, Niels
 CORPORATE SOURCE: Department of Medicinal Chemistry, LEO Pharma, Ballerup, K-2750, Den.
 SOURCE: Journal of Organic Chemistry (2004), 69(15), 4936-4947
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:190567
 GI




AB Substituted aryl aminobenzophenone p38 MAP kinase inhibitors, e.g., I, were synthesized in good to excellent yields using palladium-catalyzed aryl amination under conditions of microwave irradiation. Various ligands have been screened, and the reaction conditions were optimized. These coupling reactions were suitable for various anilines and aryl bromides that bear a variety of functional groups. Some leaving groups (iodides, chlorides, triflates, and tosylates) other than bromides have also been investigated. By this method, a large number of aryl aminobenzophenone p38 MAP kinase inhibitors were prepared in short order.

IT 740815-05-8P 740815-11-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(microwave-assisted preparation of (arylamino)benzophenones via palladium-catalyzed amination of aryl halides, triflates, or tosylates with aminobenzophenones in the presence of a biarylphosphine ligand)


RN 740815-05-8 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl]phenyl- (CA INDEX NAME)



RN 740815-11-6 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](2-methylphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 30

THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

REFERENCE COUNT: 45

THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:465522 CAPLUS

DOCUMENT NUMBER: 141:116459

TITLE: SAR of benzoylpyridines and benzophenones as p38 α MAP kinase inhibitors with oral activity

AUTHOR(S): Revesz, Laszlo; Blum, Ernst; Di Padova, Franco E.; Buhl, Thomas; Feifel, Roland; Gram, Hermann; Hiestand, Peter; Manning, Ute; Rucklin, Gerard

CORPORATE SOURCE: Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, Basel, CH-4002, Switz.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3601-3605

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:116459

AB Benzoylpyridines and benzophenones were synthesized and evaluated in vitro as p38 α inhibitors and in vivo in several models of rheumatoid arthritis. Oral activity was found to depend upon substitution: 1,1-dimethylpropynylamine substituted benzophenone 10b (IC₅₀: 14 nM) and pyridinoyl substituted benzimidazole 17b (IC₅₀: 21 nM) showed highest efficacy and selectivity with ED₅₀s of 9.5 and 8.6 mg/kg po in CIA.

IT 464190-04-3P 464190-06-5P 464190-09-8P


464190-30-5P 724767-87-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antiarthritic structure activity relationships of benzoylpyridines and benzophenones as p38 α MAP kinase inhibitors)


RN 464190-04-3 CAPLUS

CN Methanone, (2-chlorophenyl) [4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 464190-06-5 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl] (2-methoxyphenyl)- (CA INDEX NAME)



RN 464190-09-8 CAPLUS


CN Methanone, [5-(3-amino-3-methyl-1-butyn-1-yl)-2-methoxyphenyl][4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



RN 464190-30-5 CAPLUS


CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-[(1E)-2-(4-hydroxy-1-methyl-4-piperidiny)ethenyl]-2-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 724767-87-7 CAPLUS

CN Methanone, [5-(3-amino-3-methylbutyl)-2-methoxyphenyl][4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



IT 724767-90-2P 724767-99-1P 724768-00-7P
724768-01-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(antiarthritic structure activity relationships of benzoylpyridines and benzophenones as p38 α MAP kinase inhibitors)


RN 724767-90-2 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-[2-(4-hydroxy-1-methyl-4-piperidiny)ethyl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 724767-99-1 CAPLUS

CN Methanone, [5-(3-amino-3-methyl-1-butyn-1-yl)-2-chlorophenyl][4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 724768-00-7 CAPLUS

CN Methanone, (6-chloro-2-methyl-1H-benzimidazol-5-yl)[4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 724768-01-8 CAPLUS


CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl](6-methoxy-2-methyl-1H-benzimidazol-5-yl)- (CA INDEX NAME)




IT 464190-38-3P 724767-85-5P 784144-63-4P
 784144-69-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (antiarthritic structure activity relationships of benzoylpyridines and
 benzophenones as p38 α MAP kinase inhibitors)
 RN 464190-38-3 CAPLUS
 CN Methanone, (5-methoxy-2-methoxyphenyl) [4-[(2,4-difluorophenyl)amino]phenyl]-
 (CA INDEX NAME)



RN 724767-85-5 CAPLUS
 CN Methanone, (5-bromo-2-chlorophenyl) [4-[(2,4-difluorophenyl)amino]phenyl]-
 (CA INDEX NAME)




RN 784144-63-4 CAPLUS
 CN Methanone, [5-chloro-2-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-
 benzimidazol-6-yl] [4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)



RN 784144-69-0 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-methoxy-2-methyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-6-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:754202 CAPLUS

DOCUMENT NUMBER: 137:279216

TITLE: Preparation of halogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF

INVENTOR(S): Revesz, Laszlo

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076447	A1	20021003	WO 2002-EP3267	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002251070	A1	20021008	AU 2002-251070	20020322
EP 1379234	A1	20040114	EP 2002-719997	20020322

EP 1379234 B1 20060329
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 AT 321547 T 20060415 AT 2002-719997 20020322
 PT 1379234 T 20060731 PT 2002-719997 20020322
 ES 2259704 T3 20061016 ES 2002-719997 20020322
 US 20040097731 A1 20040520 US 2003-471568 20030911
 US 6919336 B2 20050719
 PRIORITY APPLN. INFO.: GB 2001-7368 A 20010323
 WO 2002-EP3267 W 20020322
 OTHER SOURCE(S): MARPAT 137:279216
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, halo, alkoxy, alkyl; R2 = H, heterocyclyl, alkyl, alkenyl, alkynyl, alkoxy; R3 = H, heterocyclyl, alkyl, alkenyl, alkynyl, alkoxy; R4 = one, tow, or three independent halo; X = N, CH], pharmaceutically acceptable and cleavable esters thereof and acid addition salts thereof are prepared as MAP kinase inhibitors and are useful pharmaceutically for treating TNF α and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis. Thus, the title compound II was prepared from 1,4-dibromobenzene, 2-chlorobenzaldehyde, Jones oxidation, and amination with 2,4-difluoroaniline.

IT 464190-38-3P
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
 (preparation process of halogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF)

RN 464190-38-3 CAPLUS

CN Methanone, (5-bromo-2-methoxyphenyl)[4-[(2,4-difluorophenyl)amino]phenyl]-
 (CA INDEX NAME)




IT 464190-04-3P 464190-06-5P 464190-07-6P
 464190-08-7P 464190-09-8P 464190-10-1P
 464190-11-2P 464190-13-4P 464190-15-6P
 464190-16-7P 464190-29-2P 464190-30-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation process of halogenated aminobenzophenones and
aminobenzoylpyridines as inhibitors of IL-1 and TNF)


RN 464190-04-3 CAPLUS

CN Methanone, (2-chlorophenyl)[4-[(2,4-difluorophenyl)amino]phenyl]- (CA
INDEX NAME)




RN 464190-06-5 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl](2-methoxyphenyl)- (CA
INDEX NAME)




RN 464190-07-6 CAPLUS

CN Methanone, [2-chloro-5-(4-pyridinyl)phenyl][4-[(2,4-
difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 464190-08-7 CAPLUS

CN Methanone, [2-chloro-5-[2-(4-morpholinyl)ethoxy]phenyl][4-[(2,4-
difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 464190-09-8 CAPLUS

CN Methanone, [5-(3-amino-3-methyl-1-butyn-1-yl)-2-methoxyphenyl][4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 464190-10-1 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-[3-(dimethylamino)-1-propyn-1-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 464190-11-2 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][2-methoxy-5-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]- (CA INDEX NAME)



RN 464190-13-4 CAPLUS


CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][2-methoxy-5-[3-(4-methyl-1-piperazinyl)-1-propyn-1-yl]phenyl]- (CA INDEX NAME)



RN 464190-15-6 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][2-methoxy-5-[(1E)-3-(4-morpholinyl)-1-propen-1-yl]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 464190-16-7 CAPLUS


CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-[(1E)-3-(dimethylamino)-1-propen-1-yl]-2-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 464190-29-2 CAPLUS


CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-[(4-hydroxy-1-methyl-4-piperidiny)ethynyl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 464190-30-5 CAPLUS

CN Methanone, [4-[(2,4-difluorophenyl)amino]phenyl][5-[(1E)-2-(4-hydroxy-1-methyl-4-piperidiny)ethenyl]-2-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:380562 CAPLUS

DOCUMENT NUMBER: 134:366881

TITLE: Preparation of triazoles as farnesyl transferase inhibitors

INVENTOR(S): Saha, Ashis Kumar; End, David William; De Corte, Bart Lieven Daniel; Breslin, Henry Joseph; Liu, Li

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036395	A1	20010525	WO 2000-EP11393	20001115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				

YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2389280	A1	20010525	CA 2000-2389280	20001115
CA 2389280	C	20090127		
EP 1232147	A1	20020821	EP 2000-988714	20001115
EP 1232147	B1	20080402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514804	T	20030422	JP 2001-538884	20001115
AU 779426	B2	20050127	AU 2001-25063	20001115
AT 391123	T	20080415	AT 2000-988714	20001115
ES 2304996	T3	20081101	ES 2000-988714	20001115
US 7049324	B1	20060523	US 2002-130322	20020513
US 20050234117	A1	20051020	US 2005-143814	20050602
US 7511061	B2	20090331		
US 20080103150	A1	20080501	US 2007-926858	20071029
PRIORITY APPLN. INFO.:			US 1999-165434P	P 19991115
			WO 2000-EP11393	W 20001115
			US 2002-130322	A3 20020513
			US 2005-143814	A1 20050602

OTHER SOURCE(S): MARPAT 134:366881
 GI



AB The title compds. [I; L1, L2 = YR1; R1 = H, CN, aryl, (un)substituted heterocyclyl; Z1Z2:Z3 = NN:CH, NCH:N, CHN:N; X = SO2, (CH2)n (n = 1-4), CO, etc.; R2 = aryl, (un)substituted cycloalkyl, etc.; R3 = aryl, NR5R6,

(un)substituted heterocyclyl, etc.; R4 = H, aryl, cycloalkyl, etc.; R5, R6 = H, (un)substituted heterocyclyl, aryl, etc.] and their N-oxides, addition salts, quaternary amines which are useful as novel class of peptidomimetic FTPase inhibitors and also show antiviral activity against RSV, were prepared E.g., a 4-step synthesis of the triazole II which showed an inhibition of FTPase activity of at least 10% at 10⁻⁷ M, was given.

IT 340729-82-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazoles as farnesyl transferase inhibitors)


RN 340729-82-0 CAPLUS

CN Benzonitrile, 4-[[3-[[[(4-benzoylphenyl)(2,4-difluorophenyl)amino]methyl]-4H-1,2,4-triazol-4-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 340729-81-9


CMF C30 H21 F2 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

51.76

237.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.38

-7.38

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 22:03:26 ON 02 AUG 2009